<DOC>
	<DOCNO>NCT00929279</DOCNO>
	<brief_summary>In full responder clopidogrel schedule undergo PCI NSTEACS , use abciximab bolus plus 600 mg clopidogrel load dose result non-inferior inhibition platelet aggregation 4 hour measure LTA ( 20micromol ADP ) compare abciximab plus infusion 300 mg clopidogrel load dose .</brief_summary>
	<brief_title>Efficacy Abciximab Bolus Only Regimen Providing Inhibition Platelet Action Over Time</brief_title>
	<detailed_description>Based outcome EPIC trial , sub-optimal result single abciximab bolus compare bolus infusion , recommend prolong platelet inhibition 12h infusion abciximab initial bolus administration patient undergo percutaneous coronary intervention ( PCI ) . However , low outcome single bolus group EPIC study entirely drive rate urgent repeat revascularization 30 day ( 3•6 percent bolus group versus 0•8 percent bolus infusion group , p &lt; 0.001 ) , complication probably related lack stent use time . Importantly , significant difference term death myocardial infarction ( MI ) . Moreover , use clopidogrel patient undergoing coronary stenting may currently reduce need infusion single abciximab bolus likely soon come availably even potent oral thienopyridines faster onset action prasugrel may contribute make post-bolus abciximab infusion marginal clinical benefit . Yet , know infusion , compare bolus regimen increase bleed rate incidence thrombocytopenia . Thus , bolus regimen potential maintain protection ischemic complication patient undergo PCI optimize safety profile treatment current era intervention base stent thienopyridines fast onset action . The CLEAR-PLATELETS study recently show 600 mg clopidogrel affect degree platelet inhibition throughout infusion eptifibatide , consistent notion glycoprotein IIb/IIIa inhibition steady state lead near maximal platelet blockade . No study far investigated effect clopidogrel , give high load dose , patient treat abciximab bolus . In particular , know whether administration clopidogrel high load dose may prolong effect abciximab bolus degree platelet inhibition time point combination abciximab bolus clopidogrel may become suboptimal term platelet inhibition compare currently recommend 12h infusion abciximab initial bolus administration . This information would lead relevant clinical implication may define time frame safe effective intervention bolus abciximab current practice . This single-centre , double-blind prospective randomize pharmacodynamic investigation 2 antiplatelet regimen patient undergo coronary stenting non-ST segment elevation acute coronary syndrome ( NSTECACS ) : 1 . Abciximab bolus follow infusion plus on-label clopidogrel administration 300 mg load dose . 2. abciximab bolus without infusion plus high loading dose clopidogrel 600 mg The objective investigation test hypothesis administration abciximab bolus plus high loading dose clopidogrel 600 mg provide non inferior level inhibition platelet aggregation 4 hour administration compare abciximab bolus follow standard infusion combination clopidogrel load dose 300 mg patient normal response clopidogrel ( evaluate 14-30 day ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Both following : Age &gt; 18 year Symptoms ischemia increase occur rest , last episode occur 24 hour randomization ; AND least one following : An elevated cardiac troponin T level ( ≥0.015 μg per liter ) ; The presence ischemic change assess electrocardiography ( defined STsegment depression transient STsegment elevation exceed 0.05 mV , Twave inversion ≥0.2 mV two contiguous lead ) A documented history coronary artery disease evidence previous myocardial infarction , finding previous coronary angiography , positive exercise test . The exclusion criterion : administration fibrinolytic GP IIb IIIa inhibitor treatment current AMI within 1 month history bleed diathesis know sensitivity abciximab , component product murine monoclonal antibody major surgery trauma within 30 day active bleed previous stroke last six month oral anticoagulant therapy preexist thrombocytopenia ; vasculitis ; hypertensive retinopathy ; severe hepatic failure , severe renal failure require haemodialysis document allergy/intolerance contraindication clopidogrel inability assume clopidogrel consecutive daily basis minimum 30 day , heparin aspirin uncontrolled hypertension ( systolic diastolic arterial pressure &gt; 180 mmHg 120 , respectively , despite medical therapy ) limit life expectancy , e.g . neoplasm , others inability obtain informed consent pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Abciximab</keyword>
	<keyword>Bolus</keyword>
	<keyword>Infusion</keyword>
	<keyword>platelet inhibition</keyword>
	<keyword>Non ST segment elevation acute coronary syndrome</keyword>
</DOC>